Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.58 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.49 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.43 |
| ▸ | TEC | P42680 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.42 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.42 |
| ▸ | TXK | P42681 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29313498 | 0.89 | EGFR (0.53) | EGFRKCNK3KCNK9NPC1RAB9A | |
| SCHEMBL20985290 | 0.88 | EGFR (0.67) | EGFRKCNK3KCNK9RAB9ALMNA | |
| SCHEMBL16755391 | 0.82 | EGFR (0.61) | EGFRKCNK3KCNK9NPC1RAB9A | |
| SCHEMBL16755417 | 0.81 | EGFR (0.80) | EGFRKCNK3KCNK9LMNATEC | |
| SCHEMBL16755448 | 0.80 | EGFR (0.82) | EGFRKCNK3KCNK9NPC1RAB9A | |
| SCHEMBL16755389 | 0.78 | EGFR (0.76) | EGFRNPC1RAB9ALMNAHPGD | |
| SCHEMBL16755407 | 0.77 | EGFR (0.53) | EGFRNPC1RAB9ALMNAATM | |
| SCHEMBL16767960 | 0.77 | EGFR (0.57) | EGFRNPC1RAB9ALMNAHPGD | |
| SCHEMBL29313506 | 0.76 | IRAK4 (0.62) | EGFRIRAK4 | |
| SCHEMBL21025638 | 0.75 | MAP3K7 (0.69) | EGFRKCNK3LMNAIRAK4MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | EGFR 349/4885KCNK3 3609/4885KCNK9 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.